Home > Haematology > ASH 2019 > Late-Breaking Abstracts > Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance

Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance

Presented By
Prof. Gill Singh, University of Hong Kong, China
Conference
ASH 2019
Maintenance therapy with arsenic trioxide (oral-As2O3), all-trans-retinoic acid (ATRA), and ascorbic acid in patients experiencing their first complete remission (CR1) from acute promyelocytic leukaemia (APL) was safe and resulted in excellent long-term survival. Prof. Gill Singh (University of Hong Kong, China) pointed towards the lack of data on the long-term outcomes of patients receiving prolonged maintenance with oral-As2O3-based regimens in CR1 following non-arsenic-based induction [1]. In the current study, adult APL patients (median age 46) in CR1 (n=129) were recruited for maintenance treatment with oral-As2O3 (10 mg/day), ATRA (45mg/m2/day in 2 divided doses), and ascorbic acid (1 g/day) (AAA). AAA was administered for 2 weeks every 2 months for a total of 2 years. Prior induction treatment comprised ATRA (45 mg/m2/day in 2 divided doses for 42 days) and daunorubicin (50 mg/m2/day for 3 days). Consolidation compri...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on